Harnessing Digital Therapeutics to Improve Glycemic Control in Type 2 Diabetes: Insights from the BRIGHT Trial
Highlight
The BRIGHT trial is a pivotal randomized controlled study assessing AspyreRx, an FDA-approved digital therapeutic that delivers cognitive behavioral therapy to improve glycemic control in patients with type 2 diabetes who experience residual hyperglycemia despite stable pharmacotherapy. The trial adopts a pragmatic, virtual, and decentralized design to enhance the generalizability of findings across diverse clinical settings. It aims to establish both short-term (90 and 180 days) and long-term efficacy and safety outcomes, alongside impacts on healthcare utilization and medication use.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.